Color keeps GSK generic off the market

Share this article:
Color keeps GSK generic off the market
Sandoz's AirFluSal Forspiro

A purple casing is keeping Sandoz from being able to market its generic of GlaxoSmithKline's COPD drug Advair in Germany.

The Wall Street Journal reports that GSK filed a preliminary injunction against the Novartis generics division because the Sandoz inhaler for its AirFluSal Forspiro inhaler is purple, just like the inhaler for GSK's Advair (known as Seretide and Viani), claiming unfair competition.

"Glaxo says it believes customers recognize the color purple as indicating its own product and Forspiro's appearance could lead to confusion among patients, pharmacists and healthcare providers,” reports the WSJ.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.